The antiserum was produced against synthesized peptide derived from human PTEN around the phosphorylation site of Ser385. AA range:370-400
Alternative Names:
PTEN, MMAC1, TEP1, Phosphatidylinositol 3, 4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN, Mutated in multiple advanced cancers 1, Phosphatase and tensin homolog
This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. The use of a non-canonical (CUG) upstream initiation site produces a longer isoform that initiates translation with a leucine, and is thought to be preferentially associated with the mitochondrial inner membrane. This longer isoform may help regulate ener
Immunohistochemistry: 1/100 - 1/300. ELISA: 1/5000. Not yet tested in other applications.
Immunohistochemistry analysis of paraffin-embedded human breast cancer, using PTEN (Phospho-Ser385) Antibody. The picture on the right is blocked with the PTEN (Phospho-Ser385) peptide.
* VAT and and shipping costs not included. Errors and price changes excepted
